A Prospective, Multicentre study to evaluate the Safety and Efficacy of Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold in patients with Coronary Artery Disease
Latest Information Update: 04 Dec 2020
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease
- Focus First in man; Therapeutic Use
- Acronyms FAST
- 18 Oct 2020 Final IVUS and OCT results presented at the 32nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 18 Mar 2019 Results assessing acute and mid-term performance of the RENUVIA bioresorbable scaffold using serial IVUS and OCT, presented at the 68th Annual Scientific Session of the American College of Cardiology
- 03 Jan 2018 New trial record